Organoid Culture Medium Using Wnt Activator Instead of R-Spondin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high cost and instability of R-spondin, a protein essential for organoid culture, hinder efficient and economical mass production of clinically applicable organoids, necessitating a stable and cost-effective replacement.
Innovation Solution
A compound of chemical formula 1, such as RS-246204, is used to activate the Wnt signal pathway, replacing R-spondin in the culture medium, maintaining organoid stability and morphology while reducing costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If R-spondin is used in the culture medium for organoid culturing, then organoid growth and maintenance are supported, but the cost is extremely high and stability is difficult to maintain
Solution Approach 1:
The patent replaces expensive R-spondin protein with a small molecule compound (Formula 1) that can be synthesized at low cost. This small molecule acts as a Wnt signal pathway activator, providing the necessary biological function without the high production costs associated with protein purification. The compound can be added to culture medium at reasonable concentrations to support organoid growth economically.
Solution Approach 2:
The patent changes the chemical form from a protein (R-spondin) to a small molecule compound (Formula 1). This parameter change enables the substance to be more stable in culture medium and easier to synthesize at scale, thereby reducing cost while maintaining or improving reliability of organoid culture.
2Reliability
If R-spondin is added to the culture medium, then organoid culturing is enabled, but the substance shows poor stability and inconsistent levels
Solution Approach 1:
The patent replaces the unstable R-spondin protein with a chemically stable small molecule compound (Formula 1). Small molecules generally exhibit better stability in culture conditions compared to proteins, which are prone to degradation. This substitution maintains consistent active levels in the culture medium, improving reliability of organoid culturing.
Solution Approach 2:
The patent changes the molecular characteristics from protein-based (R-spondin) to small molecule-based (Formula 1). This parameter change fundamentally improves stability properties, as small molecules are more resistant to enzymatic degradation and environmental variations, ensuring consistent culture conditions.
3Productivity
If mass culturing of organoids is performed for therapeutic use, then clinical applicability is achieved, but the extreme cost of R-spondin makes it economically inefficient
Solution Approach 1:
The patent enables mass culturing of organoids by replacing R-spondin with a cost-effective small molecule compound (Formula 1). This substitution reduces the per-unit cost of culture medium, making large-scale production economically viable for therapeutic applications. The compound can be synthesized at scale without the expensive purification processes required for proteins.
Solution Approach 2:
The patent changes the culture system from protein-dependent to small molecule-dependent, fundamentally altering the cost structure. Small molecules are generally more amenable to large-scale synthesis with lower costs, enabling productive mass culturing of organoids for clinical use.
Data Source
AI summary
The present invention relates to a composition for culturing organoids and a method for culturing organoids by using the same. Since the present invention includes a compound, which can replace an essential protein component in a conventional medium, consistent stability during organoid culturing can be maintained and culturing can be performed at low cost.